文献速递前列腺癌

实体器官移植患者前列腺癌主动监测:匹配研究与文献综述

Prostate cancer active surveillance in solid organ transplant: a matched study and literature review.
PubMed 文献 · BJU Int · 2025-05-14

本研究评估实体器官移植(SOT)患者前列腺癌主动监测(AS)的安全性,将32例SOT AS患者与99例非SOT AS患者按年龄、种族、PSA和Gleason分级分组匹配。结果显示两组在进展至根治治疗、分级再分类及GGG方面无显著差异,无全身疾病进展或前列腺癌特异性死亡。文献综述纳入11项研究共99例SOT AS患者,未发现安全性信号。

要点

  • SOT患者AS的中位时间为4.7年,非SOT为4.98年,两组无显著差异(P=0.87)。
  • SOT组28.1%、非SOT组39.4%进展至根治治疗(P=0.30),分级再分类无差异。
  • 文献综述未发现SOT患者AS的安全性信号,但数据有限需进一步研究。

核心结论

  • 在SOT合并前列腺癌患者中,主动监测策略似乎是安全的,结局与非SOT患者相似。
  • 文献综述未发现SOT患者AS的安全性信号,但相关数据匮乏,需进一步研究。

研究设计与样本

  • 回顾性研究,纳入接受肾、肝、心、肺移植且诊断前列腺癌并进入AS的SOT患者32例。
  • 采用前瞻性收集信息,按年龄、种族、PSA和Gleason分级分组与非SOT AS患者99例进行匹配。
  • 按照PRISMA指南进行范围综述,检索并回顾相关文献。

主要发现

  • 34%的SOT患者在移植前入组AS。
  • SOT组和非SOT组的中位AS时间分别为4.7年和4.98年(P=0.87)。
  • 53%的SOT患者和54.5%的非SOT患者仍在AS中(P=0.99)。
  • 28.1%的SOT患者和39.4%的非SOT患者进展至根治治疗(P=0.30),分级再分类或根治治疗时GGG无差异。
  • 未发生全身疾病进展或前列腺癌特异性死亡。

临床怎么用

  • 对于SOT合并前列腺癌患者,主动监测可作为安全的管理策略,结局与非SOT患者相似。
  • 需注意SOT患者AS数据有限,临床决策应个体化并密切随访。

局限性

  • 样本量较小(SOT组32例),可能影响统计效能。
  • 回顾性研究设计存在固有偏倚。
  • 文献综述中SOT患者AS数据匮乏,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate outcomes of prostate cancer (PCa) active surveillance (AS) in patients with versus without solid organ transplant (SOT), as the safety of PCa AS in patients with SOT remains understudied. We also performed a literature review to identify all studies describing PCa AS in patients with SOT. PATIENTS AND METHODS: A retrospective study was conducted for patients with SOT (kidney, liver, heart, lung) with a diagnosis of PCa enrolled into AS either before or after SOT. Using prospectively collected information, they were matched with non-SOT AS patients at PCa diagnosis by age, race, prostate-specific antigen, and Gleason Grade Group (GGG). A scoping review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: A total of 32 SOT AS patients were matched with 99 non-SOT AS patients. After matching, there was no significant difference in baseline demographics. 34% were enrolled into AS before SOT. The median time on AS for patients with and without SOT was 4.7 and 4.98 years, respectively (P = 0.87). In all, 53% of patients with SOT and 54.5% those without SOT were still on AS (P = 0.99). In all, 28.1% of patients with and 39.4% without SOT progressed to definitive treatment (P = 0.30), and there were no differences in rates of grade re-classification or GGG at definitive treatment. No systemic disease progression or PCa-specific deaths occurred. In the literature, we identified and reviewed 11 studies and found 99 patients enrolled into AS either before (n = 33) or after (n = 66) SOT. We did not identify a safety signal. CONCLUSION: We present the largest series of patients with PCa on AS with SOT. In patients with SOT and PCa on AS, a surveillance strategy appears safe and has similar outcomes as those without SOT on AS. Our review found a paucity of AS data in the SOT setting suggesting that further research is warranted.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Alshak MN, Higgins MI, Grutman AJ, et al. Prostate cancer active surveillance in solid organ transplant: a matched study and literature review. BJU Int. 2025. PMID: 40365989. doi:10.1111/bju.16777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。